This study is designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of OLX72021 in medically healthy men with mild to moderate androgenetic alopecia.
Adult male.
18 to 59 years.
Androgenetic Alopecia (Hamilton-Norwood III-V).
Body mass index (BMI) ≥ 18.0 kg/m2, with a body weight ≥ 50 kg at screening.
History or presence of significant pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, or neurological disease, including any acute illness or major surgery within the past 3 months determined by the PI to be clinically significant.
Uncontrolled diabetes mellitus.
Immunodeficiency disorders.
History of clinically significant heart disease.
Olix Pharmaceuticals, Inc.
Lead sponsor
Avance Clinical Pty Ltd.
Collaborator